New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 17, 2014
09:15 EDTVRSN, SINA, ICPT, FPRX, GMCR, YHOO, HNR, LO, WPX, HTZ, JASO, BMYOn The Fly: Pre-market Movers
UP AFTER EARNINGS: JA Solar (JASO), up 16%. ALSO HIGHER: Five Prime (FPRX), up 13% after signing collaborative agreement with Bristol-Myers (BMY)... SINA (SINA), up 9% after files preliminary prospectus to raise up to $500M in U.S. IPO of Weibo unit... Hertz (HTZ), up 7.7% after Financial Times says the company is nearing a spin-off of its construction equipment rental business... Lorillard (LO), up 2.5% following upgrade at Goldman... Keurig Green Mountain (GMCR), up 3.7% after being selected to replace WPX Energy (WPX) in S&P 500 as of March 21 close... Yahoo (YHOO), up 4.1% after Alibaba announces plan to begin U.S. IPO process... LOWER: Intercept (ICPT), down 0.6% after disclosing two serious adverse events in Phase 2 FLINT trial... Harvest Natural (HNR), down 10% after earnings report. VeriSign (VRSN), down 5% after the National Telecommunications and Information Administration said it intends to transition key Internet domain name functions.
News For YHOO;SINA;HTZ;GMCR;VRSN;WPX;FPRX;BMY;LO;ICPT;JASO;HNR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 >>
January 28, 2016
12:42 EDTBMYBristol-Myers says EU approves Daklinza for treatment of chronic hepatitis C
Bristol-Myers Squibb announced that the European Commission has approved Daklinza for the treatment of chronic hepatitis C in three new patient populations. The expanded label allows for the use of Daklinza in combination with sofosbuvir in HCV patients with decompensated cirrhosis, HIV-1 coinfection, and post-liver transplant recurrence of HCV in all 28 Member States of the European Union. Daklinza is already approved by the European Commission for use in combination with other medicinal products across genotypes 1, 2, 3 and 4 for the treatment of chronic HCV infection in adults, and the Daklinza + sofosbuvir regimen is the only approved 12-week, all-oral treatment for genotype 3 HCV patients without cirrhosis. The new indications are based on data from the ALLY-1 clinical trial and ALLY-2 clinical trial. The recommended treatment regimens and durations are as follows:
11:30 EDTYHOOYahoo pares down Latin American operations, TechCrunch says
Yahoo is paring down its regional operations in Latin America and has closed its offices in Mexico City and Buenos Aires, Argentina, says Tech Crunch. The company is maintaining operations in Sao Paulo, Brazil and Coral Gables, Florida. added TechCrunch. Reference Link
10:32 EDTGMCROptions with increasing implied volatility: RAD GMCR
09:27 EDTBMYBristol-Myers reports Q4 US revenue $2.3B
Subscribe for More Information
09:27 EDTBMYBristol-Myers sees FY16 non-GAAP EPS $2.30-$2.40, consensus $2.29
Sees FY16 revenue up in mid-single digit range, consensus $17.4B. Sees FY16 gross margin as percentage of revenue ot be approximately 75%-76%. Sees FY16 marketing, sales and administrative expenses decreasing in mid-single digit range. Sees FY16 R&D expenses increasing in high-single digit range. Sees FY16 effective tax rate between 21%-22%.
09:25 EDTBMYBristol-Myers reports Q4 non-GAAP EPS 38c, consensus 28c
Reports Q4 revenue $4.29B, consensus $4.15B.
08:33 EDTYHOOOptions expected to be active
Subscribe for More Information
07:11 EDTBMYBristol-Myers: DMC concluded that CheckMate Phase 3 study met primary endpoint
07:00 EDTBMYBristol-Myers says CheckMate-141 Opdivo Phase 3 trial stopped early
Bristol-Myers Squibb announced that a randomized Phase 3 study evaluating Opdivo versus investigator's choice in patients with recurrent or metastatic platinum-refractory squamous cell carcinoma of the head and neck was stopped early because an assessment conducted by the independent Data Monitoring Committee concluded that the study met its primary endpoint, demonstrating superior overall survival in patients receiving Opdivo compared to the control arm. The company looks forward to sharing these data with health authorities soon. "With the results of CheckMate -141, Opdivo moves closer to providing a potential treatment option for patients with head and neck cancer, a cancer with a high unmet need and limited treatment options," said Michael Giordano, M.D., senior vice president, head of Oncology Development, Bristol-Myers Squibb. "We look forward to continuing to advance the Opdivo clinical development program in hard-to-treat cancers, such as head and neck cancer." CheckMate -141 investigators have been informed of the decision to stop the trial early and Bristol-Myers Squibb is working to ensure that eligible patients be provided the opportunity to continue or start treatment with Opdivo as part of the company's commitment to providing patient access to Opdivo, and characterizing long-term survival. The company will complete a full evaluation of the final CheckMate -141 data, and work with investigators on the future presentation and publication of the results.
06:56 EDTYHOOVerizon denies report of bidding on Yahoo core business, CTFN says
Verizon (VZ) spokesperson for Bob Varettoni said the New York Post "was wrong" in reporting on January 23 that the telecom company made an offer to acquire Yahoo's (YHOO) Internet search business, reported CTFN. Varettoni told the publication: "The rumor's false...We've made no offer to acquire Yahoo." Reference Link
06:30 EDTYHOOYahoo starts restructuring with 'invest/maintain/kill' list, Re/code reports
Subscribe for More Information
06:17 EDTYHOOYahoo starts restructuring with 'invest/maintain/kill' list, Re/code reports
Subscribe for More Information
05:44 EDTYHOOSpringOwl calls for Yahoo, Viacom to seek partners, Reuters reports
SpringOwl Asset Management, which holds undisclosed stakes in Yahoo (YHOO) and Viacom (VIA), is urging the boards of both companies to seek investments from strategic partner, Reuters reports, citing an article that is set to be published today. SpringOwl managing director Eric Jackson says that "Although some shareholders of both Yahoo and Viacom think that a simple sale or break-up of both companies is the best way to create value for shareholders, we believe that both companies could benefit from their own version of the 'Buffett Convert,'" and that while stakes of investors would be diluted if an outside investor steps in, but "they would still be better off because their shares would likely get re-rated upwards substantially with this new partner sitting around the board table." Jackson believes Yahoo should seek outside investment from Liberty Media (LMCA), Verizon (VZ) or AT&T (T), while Viacom would benefit from Alibaba (BABA), Amazon (AMZN) or AMC Entertainment (AMC). Reference Link
January 27, 2016
14:34 EDTBMYNotable companies reporting before tomorrow's open
Subscribe for More Information
14:17 EDTBMYBristol-Myers technical comments before earnings news
Subscribe for More Information
13:55 EDTBMYBristol-Myers volatility elevated into Q4 and outlook
Bristol-Myers Black & Decker January weekly call option implied volatility is at 49, February is at 30; compared to its 52-week range of 18 to 43, suggesting large near term price movement into the expected release of Q4 results on January 28.
10:36 EDTGMCROptions with increasing implied volatility: SNDK GMCR
08:42 EDTYHOOIAC's Diller says would not buy Yahoo, Bloomberg reports
IAC (IAC) Chairman Barry Diller said Yahoo (YHOO) can be a standalone business, adding that he would not buy the company, according to Bloomberg. Diller said Yahoo is only worth buying at a "serious discount," according to Bloomberg.
January 26, 2016
10:48 EDTGMCRTreeHouse may benefit from strategy shifts, says Detwiler Fenton
Detwiler Fenton said TreeHouse (THS) may benefit from Keurig Green Mountain's (GMCR) and Starbucks' (SBUX) focust shift into new products. Keurig Green Mountain dropping of its private-label business opens the door for TreeHouse to take market share, the firm's analyst said. Detwiler sees TreeHouse benefiting from Starbucks' shifts away from Keurig Green Mountain and into other product opportunities.
10:32 EDTGMCROptions with increasing implied volatility: CLDX SNDK GMCR RAD
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use